

**Supplementary Table 1.** Primer sequences used for real-time PCR.

<b>Gene</b>	<b>Sense</b>	<b>Anti-sense</b>
CEH	ACGCTTGCCAGACCCTCTTC	CTCAGCCACTTCAGCATCGC
Cyp27a1	TCATCGCACAAAGGAGAGCAATG	CGTTAAGGCATCCGTGTAGAGC
Cyp7a1	TTGTTCAAGACCGCACATAAACCC	CGTAGACGGATCAGTTCAGAGACC
Cyp7b1	TTTCAGTCCACTTCACCAGAGAAC	GCACAGCCTCAGAACCTCAAGA
Cyp8b1	CCCTGAGCCCACAGCCTTC	GGATCTTCTTGCCGACTTGTAG
FXR	TGCGATTACCACCAACCACCTG	CCGAACCTTAGCCAGCCACCA
LRH-1	GGCTCCGTTCCCTTCAGTCG	TTCACCTGCTCTGGACACCTTC
Shp	AAGGGCACGATCCTCTCAACC	CAGGGCTCCAAGACTTCACACA


Abbreviations: CEH, cholesteryl ester hydrolase; Cyp27a1, sterol 27-hydroxylase; Cyp7a1, 7- $\alpha$ -hydroxylase; Cyp7b1, oxysterol 7- $\alpha$ -hydroxylase; Cyp8b1, sterol 12- $\alpha$ -hydroxylase; FXR, farnesoid X receptor; LRH-1, liver-receptor homolog-1; Shp, small heterodimer partner

**Supplementary Table 2.** Antibody details and conditions used for western blotting (WB) and immunohistochemistry (IHC).


Antibody	Supplier	Catalog #	Application	Dilution
α-ABCG5	Santa Cruz	sc-25796	WB	1:500
α-ABCG8	Santa Cruz	sc-30111	WB	1:350
α-ACAT2	Cayman Chemicals	100027	WB	1:180
α-Bsep	Santa Cruz	sc-74500	WB	1:180
α-Bsep	Santa Cruz	sc-25571	IHC	1:200
α-F4/80	AbD Serotec	MCA497R	IHC	1:150
α-FXR	Abcam	ab28480	WB	1:500
α-HSP90	R&D systems	AF3775	WB	1:2000
α-LDLR	Abcam	ab52818	WB, IHC	1:1800, 1:200
α-LRH-1	Abcam	ab41901	WB	1:500
α-Shp	Santa Cruz	sc-23057	WB	1:200
α-SR-B1	Abcam	ab52629	WB, IHC	1:1800, 1:200
α-SREBP-2	Abcam	ab28482	WB	1:500

Abbreviations: ABC, ATP-binding cassette protein; ACAT, acyl-CoA:cholesterol acyltransferase; Bsep, bile salt exporter protein; FXR, farnesoid X receptor; LDLR, LDL-receptor; LRH-1, liver receptor homolog-1; Shp, small heterodimer partner; SR-B1, scavenger receptor B-1; SREBP-2, sterol response element binding protein-2. Antibodies were purchased from Abcam (Cambridge, UK), AbD Serotec (Oxford, UK), Cayman Chemicals (Ann Arbor, MI, USA), R&D Systems (Minneapolis, MN, USA), and Santa Cruz Biotechnology, Inc (Santa Cruz, CA. USA).


Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3



**Supplementary Figure 1. Differentially regulated pathways involved in cholesterol homeostasis.**

In addition to the pathways illustrated in Figure 2, we studied: (A) Scavenger receptor-B1 (SR-B1) protein expression, and (B) Cyp27a1, (C) Cyp7b1, (D) Cyp8b1 mRNA expression at 12- (□) and 24- (■) weeks in WT and *foz/foz* mice (*n* values as per METHODS). (E) Bile salt exporter protein (Bsep) IHC staining in 24-week WT and *foz/foz* mouse livers produced similar results to WB analyses (Figure 2). (F) ATP-binding cassette-G5 (ABCG5) protein expression in mice at 12- and 24- weeks. Scale bars represent 50  $\mu$ m. Arrows indicate positive staining.

\* $P<0.05$ , vs. diet-matched control. # $P<0.05$ , vs. genotype-matched, 0.2% cholesterol groups.

$\dagger P<0.05$ , vs. genotype-matched, 2.0% cholesterol groups.

**Supplementary Figure 2. Dietary cholesterol increases serum cholesterol, but fails to alter other lipid profiles in HF-fed WT and *foz/foz* mice.**

(A) Total serum cholesterol and (B) triglyceride (TG) levels in WT (□) and *foz/foz* (■) mice (*n* values as per METHODS) fed HF-diet containing 0, 0.2 or 2.0% (w/w) cholesterol for 24-weeks. (C) Monoacylglycerides (MAG), (D) saturated FFAs (SaFA), (E) mono-unsaturated FFAs (MuFA), and (F) poly-unsaturated FFAs (PuFA) were determined by HPLC. \* $P<0.05$ , vs. diet-matched control. # $P<0.05$ , vs. genotype-matched, 0.0% cholesterol groups.  $\dagger P<0.05$ , vs. genotype-matched, 0.2% cholesterol groups.

**Supplementary Figure 3. Comparison between LDLR localization in *foz/foz*, methionine and choline-deficient (MCD) and carbon tetrachloride-treated mice .**

LDLR localization in (A) chow- and (B) HF-fed *foz/foz* mice at 24 weeks, (C) MCD control and (D) MCD-deficient mice at 8 weeks, and (E) carbon tetrachloride- ( $\text{CCl}_4$ ) control and (F) – treated mice at 4 weeks. Scale bars represent 20  $\mu\text{m}$ .